QSV Biologics has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer. The protein, intended for clinical trials, will be manufactured at QSV’s Edmonton facility in Canada. The project, to begin immediately, will include technology transfer, scale-up and cGMP manufacturing.     Graeme Macaloney Ph.D., P.Eng., founder, president and chief executive officer of QSV, said, “We are extremely pleased and honored that Pfizer has chosen QSV Bio...